Mirus Bio launches new TransIT-PRO transfection kit for biotherapeutic protein production

NewsGuard 100/100 Score
Editorial Checklist Reviewed
Aug 19 2010Mirus Bio LLC

Mirus Bio now offers a new transfection kit ideal for biotherapeutic protein production in large pharma and biotech settings. Mirus Bio's new TransIT-PRO™ Kit will decrease time to produce usable protein by maximizing target protein yields through transient transfection. TransIT-PRO™ Kit uses animal origin free components designed for high and reproducible protein yield in suspension CHO and 293 derived cells. Since it is compatible with varied media formulations, the same media can be used for both transient and stable expression. TransIT-PRO™ outperforms linear PEI in protein yield and reproducibility while providing a cost-effective alternative to FreeStyle™ MAX.

With TransIT-PRO™ you will:

  • Achieve high protein yield in suspension CHO and 293 cells
  • Experience compatibility with multiple CHO media formulations
  • Obtain reproducible protein expression with minimal optimization
Source:

Mirus Bio LLC

Posted in: Device / Technology News | Medical Science News

Tags: , , , ,

Comments (0)

Suggested Reading

Balancing diets: study reveals plant protein's impact on nutrient levels in Americans
Blood protein could be a potential biomarker for delayed concussion recovery in children
Protein intake during pregnancy affects offspring's facial features
New insights into gas vesicle clustering in bacteria open doors for biomedical applications
Study reveals key protein's role in balancing immune response to viral infections
AI-powered method predicts protein dynamics to accelerate drug discovery
Scientists map all yeast proteins across cell cycle for the first time
Muscles in microgravity: Spaceflight duration impacts muscle protein stress markers

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Innovative approach to disrupt misfolding of tau proteins in neurodegenerative diseases